<DOC>
	<DOCNO>NCT02987972</DOCNO>
	<brief_summary>This study design evaluate safety , tolerability , immunogenicity two different lot V114 healthy infant 6 12 week ( &gt; =42 day &lt; =90 day ) age . The primary hypothesis study proportion participant receive V114 serotype specific IgG &gt; =0.35 mcg/mL pneumococcal serotypes 1 , 3 , 4 , 5 , 6A , 6B , 7F , 9V , 14 , 18C , 19A , 19F , 23F 1 month Dose 3 non-inferior recipient Prevnar 13â„¢ .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Immunogenicity Two Lots V114 Healthy Infants ( V114-008 )</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Infant approximately 2 month age ( 42 day 90 day ) , inclusive In good health Prior administration pneumococcal vaccine Known hypersensitivity component pneumococcal conjugate vaccine diphtheria toxoidcontaining vaccine Known suspect impairment immunological function History congenital acquire immunodeficiency ( eg , splenomegaly ) Mother document human immunodeficiency virus ( HIV ) infection Mother document hepatitis B surface antigenpositive test result Known history functional anatomic asplenia History failure thrive History coagulation disorder History autoimmune disease Known neurologic cognitive behavioral disorder Expects require systemic corticosteroid within 30 day vaccination trial Prior administration blood transfusion blood product , include immunoglobulin Participated another clinical trial investigational product History invasive pneumococcal disease know history culturepositive pneumococcal disease</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>